Pharmacological screening of glibenclamide solid dispersion in fructose-fed diabetic rats

In this study, our main objective was to estimate the therapeutic effectiveness of the formulated solid dispersion of glibenclamide (GSD) with improved dissolution profiles in comparison with pure GLB by means of fructose-fed diabetic rat model. To evaluate the pharmacological effectiveness of the formulated GSD, fructose-fed diabetic rat model was evolved, and the obtained consequences were compared with the conventional GLB treatment. GSD exhibited improved glucose and lipid-lowering efficacy of GSD in contrast to pure GLB after 15 days of treatment. Low dose (0.5mg/kg) and high dose (5mg/kg) of GSD showed significant lowering of blood glucose which is 6±0.2 mmol/L and 5.6±0.3 mmol/L respectively after 15 days of treatment that is much better than that of pure GLB (6.2±0.4 mmol/L). Furthermore, low dose of GSD presented approximately comparable beneficiary effects in regard to triglycerides (72.00±7.23mg/dL) total cholesterol (110.33±5.78 mg/dL), and low-density lipoprotein (67.60±5.21mg/dL) and high-density lipoprotein (28.33±1.53 mg/dL) as pure GLB after 15 days. Additionally, histological studies as well confirmed no fatty infiltration from liver by GSD as compared with GLB which was consistent with the biochemical parameters. For treating diabetes and hyperlipidaemia, the formulated GSD might be a potential substitute for traditional GLB.